Tenderwize
Zurück zur Suche

Open-house discount agreement for Cladribin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 524 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cladribin, ATC L04AA40

42/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

42 / 100

Komplexität

58 / 100

Risikofaktoren

The buyer states this is an open-house model and not a public procurement procedure in the usual sense, which may affec...

The notice says the contract documents must be submitted via the DTVP communication area and not via the offer area; us...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive pharmaceutical discount agreement for the active substance Cladribin, ATC L04AA40.
  • Supply contract under an open-house model with identical, pre-set terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Cladribin (ATC L04AA40) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 01.04.2026 to 31.03.2028, with the latest possible contract conclusion on 03.02.2028. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form by original signed documents; German language is required, and non-German documents must include a German translation.

Risiken

The buyer states this is an open-house model and not a public procurement procedure in the usual sense, which may affec...

The notice says the contract documents must be submitted via the DTVP communication area and not via the offer area; us...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house discount agreement for Cladribin

Open-house supply arrangement for pharmaceutical discount agreements concerning Cladribin, ATC L04AA40. The lot covers non-exclusive, identical and non-negotiable contract terms for interested pharmaceutical companies. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Mar 2026 - Mar 2028

Kategorie

Pharmaceutical products

Frist

Deadline Feb 03, 2028

Vergabedetails

Veröffentlichungsdatum
15 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
110061-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30